|Publication number||US960914 A|
|Publication date||Jun 7, 1910|
|Filing date||Sep 21, 1909|
|Priority date||Sep 21, 1909|
|Publication number||US 960914 A, US 960914A, US-A-960914, US960914 A, US960914A|
|Original Assignee||Arthur Heinemann|
|Export Citation||BiBTeX, EndNote, RefMan|
|Referenced by (34), Classifications (1)|
|External Links: USPTO, USPTO Assignment, Espacenet|
ARTHUR HEINEMANN, OF LONDON, ENGLAND.
PIL LS FOR THE TREATMENT OF DIABETES MELLITUS.
Specification of Letters Patent.
Application filed September 21, 1909. Serial No. 518,840.
Patented June '7, 1910.
To all whom it'may concern: 7
Be it known that I, ARTHUR HEINEMANN, a subject of the Emperor of Germany, residing at Carlton Mansions, Portsdown Road, Maida Vale, London, W., England, have invented new and useful Improvements in Pills for the Treatment of Diabetes Mellitus, of which the following is a specification.
Diabetes mellitus is a chronic disease of metabolism in which the carbohydrates contained in the food and drink taken by the sufferer are converted into glucose and pass into the urine without contributing to the depend upon the blood for their proper functions it necessarily follows that if the blood can not supply the proper nourishment to said parts the latter will become defective and the blood become charged with abnormal or poisonous matter.
To combat a disease it is necessary to remove its cause. This is effected by the introduction into the blood of a particular substance which in the case of diabetes mellitus must be such as will enable the blood to regain its ability to split up and oxidize the glucose.
The blood, like every other organic matter of vegetable or animal origin, contains enzymes which perform the necessary chemical changes. In the case of diabetes mellitus the blood of the sufferer is not of the proper composition and does not contain either the right or suflicient quantity of enzymes to properly oxidize and assimilate the carbohydrates.
According to my invention I substitute for the natural enzymes, which should be present in the blood, vegetable enzymes,- the socalled oxydases and peroxydaseswhich under certain conditions split up and oxidize the glucose, the products of which are then utilized for the nourishment of the body. But as these enzymes only act in a weak acid or neutral solution and still bet ter in an alkaline solution, and the acid condition of the blood of a diabetic patient is such as to destroy the function,-namely the possibility of utilizing sugar-of even the natural blood enzymes it is necessary to diminish or remove the acidity of the blood. For this Ipurpose I mix the vegetable enzymes wit finely pulverized alkaline salts. The vegetable enzymes and alkaline salts are then formed into pills and coated with keratin or the like, so as to prevent the acids present in the stomach from either reducing or totally annulling the effect of the alkaline enzyme mixture. The pill passes unchanged into the duodenum where it is dissolved by the alkaline liquid present in the intestine. It is then absorbed and passes into the blood, the abnormal amount of acid in the latter being neutralized, so that the natural enzymes of the blood as well as the artificially addedenzymes are able to work under physiological conditions and split up and oxidize the sugar compounds, thus enabling the latter to contribute to the nourishment of the body.
Experience has shown that nearly all vegetable enzymes having an oxidizing effect u on the carbohydrates are useful for the a ove named purpose, especially the oxydases and peroxydases of the genera cucurbita, cochlearia and beta. As regards the alkaline salts to be used those readily absorbed in the intestine such, for instance, as the carbonates of lithium, sodium, potassium and magnesium, and the oxid and peroxid of magnesium should .be employed. Since a peroxydase only acts in the presence of peroxld compounds, it is necessary to always use a peroxld, for example dioxid of magnesium with the peroxydases. The enzyme is prepared from the plant in any suitable or well known manner, such as the following. The leaves, roots or other parts of the plant are inacerated, either with-or without the addition of water, and then if required slightly fermented. The liquid so obtained which contains the enzyme in solution is thenfiltered. and the enzyme successively preci itated and purified by alcohol, ether or ot er suitable means. This constituent is like the corresponding constituent found in yeast and is now known by the same name viz. zymase. The precipitated enzyme or the liquid zymase, as the case may be,
is then mixed with the necessary proportion of alkaline salts and formed mto pills, which are then coated with keratin or other substance incapable of being dissolved by the gastric julce present in the stomach. The pills can be provided with a second coating of such nature as to make them palatable.
In the case of the genus beta the invention could be carried out in the following manner: A suitable quantity of common sugar beets, such for example as 10 kilos is thoroughly cleaned, reduced to a pulp and then subjected to a pressure of, say, 300 atmospheres by means of a suitable hydraulic press. The liquid obtained by this operation, about 7 liters, is then poured into a vessel and mixed with 700 c. c. m. of alcohol of 96% purity, so as to precipitate the sugar and mucous substance contained in the mixture. The liquid in said vessel is removed and filtered, and 45 liters of absolute alcohol added to the filtrate. The resultant precipitate is filtered and Washed with a little absolute alcohol and then placed in a closed vessel. The alcohol is then evaporated preferably at a temperature of about 20 to 30 C. by the withdrawal, by any suitable apparatus, of the air contained in said vessel. The dry powder resulting from the last step, which weighs about 20 grams, is then mixed with 20 grams of magnesium peroxid, 20 ams of lithium carbonate, and 4.8 grams 0 magnesium oxid. This mixture will be sufiicient to form 400 pills or tablets of 0.162 gram, or 24,; grains, each.
I WlSh it to be understood that although I have in the fore oin description advisedly used the wor il it is obvious that the mixture of vegeta le enzymes and alkaline salts may be pressed into the form of small tablets.
Having described my invention, what- I claim and desire to secure by Letters Patent is 1. Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases and an alkaline salt provided with a coating consistin of a substance insoluble by the gastric juices of the stomach, substantially as described.
2. Pills for the treatment of diabetes mellitus containing a compressed mixture of oxydases of the genus beta and an alkaline salt provided with a coating of' keratin, substantially as described.
,In testimony whereof I have signed my name to this specification in the presence of two subscribing witnesses.
Witnesses: ARTHUR F. ENNIS, F. L. BANDS.
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US6783546||Mar 22, 2001||Aug 31, 2004||Keraplast Technologies, Ltd.||Implantable prosthetic or tissue expanding device|
|US6849092||Mar 8, 2001||Feb 1, 2005||Keraplast Technologies, Ltd.||Implantable prosthetic or tissue expanding device|
|US6914126||Apr 10, 2002||Jul 5, 2005||Keraplast Technologies, Ltd.||Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks|
|US6989437||Apr 26, 2002||Jan 24, 2006||Keraplast Technologies, Ltd.||Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks|
|US7001987||Apr 22, 2002||Feb 21, 2006||Keraplast Technologies, Ltd.||Hydrogel with controllable mechanical, chemical, and biological properties and method for making same|
|US7001988||Sep 25, 2002||Feb 21, 2006||Keraplast Technologies, Ltd.||Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same|
|US7501485||Jan 28, 2003||Mar 10, 2009||Keraplast Technologies, Ltd.||Bioactive keratin peptides|
|US8258093||Sep 23, 2011||Sep 4, 2012||Wake Forest University Health Sciences||Wound healing compositions containing keratin biomaterials|
|US8273702||Apr 17, 2008||Sep 25, 2012||Wake Forest University Health Sciences||Wound healing compositions containing keratin biomaterials|
|US8299013||Feb 16, 2007||Oct 30, 2012||Wake Forest University Health Sciences||Clotting and healing compositions containing keratin biomaterials|
|US8324346||Feb 26, 2009||Dec 4, 2012||Keraplast Technologies, Ltd.||Bioactive keratin peptides|
|US8545893||Mar 8, 2011||Oct 1, 2013||Wake Forest University Health Sciences||Keratin biomaterials for treatment of ischemia|
|US8637231||Aug 11, 2011||Jan 28, 2014||Wake Forest University Health Sciences||Method for increasing the volume of a blood substitute with an expander comprising basic alpha keratose|
|US8920827||Oct 16, 2006||Dec 30, 2014||Wake Forest University Health Sciences||Keratin bioceramic compositions|
|US8968764||Jan 18, 2011||Mar 3, 2015||Wake Forest University Health Sciences||Nerve regeneration employing keratin biomaterials|
|US9068162||Feb 12, 2010||Jun 30, 2015||Wake Forest University Health Sciences||Keratin biomaterials for cell culture and methods of use|
|US9149566||Feb 15, 2007||Oct 6, 2015||Wake Forest University Health Sciences||Coatings and biomedical implants formed from keratin biomaterials|
|US9220754||May 16, 2013||Dec 29, 2015||Wake Forest University Health Sciences||Keratin compositions for treatment of bone deficiency or injury|
|US20030119089 *||Sep 25, 2002||Jun 26, 2003||Dyke Mark Van||Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same|
|US20030219486 *||Apr 10, 2002||Nov 27, 2003||Van Dyke Mark E.||Methods for producing, films comprising, and methods for using heterogenous crosslinked protein networks|
|US20030224052 *||Apr 22, 2002||Dec 4, 2003||Van Dyke Mark E.||Hydrogel with controllable merchanical, chemical, and biological properties and method for making same|
|US20030228353 *||Jan 28, 2003||Dec 11, 2003||Keraplast Technologies, Ltd.||Bioactive keratin peptides|
|US20040120910 *||Sep 29, 2003||Jun 24, 2004||Dyke Mark Van||Methods for producing, films comprising, and methods for using heterogeneous crosslinked protein networks|
|US20050058686 *||Jul 25, 2003||Mar 17, 2005||Mark Van Dyke||Bioactive coating for medical devices|
|US20050169963 *||Jan 31, 2005||Aug 4, 2005||Southwest Ressearch Institute||Implantable prosthetic or tissue expanding device|
|US20070166348 *||Oct 16, 2006||Jul 19, 2007||Van Dyke Mark E||Keratin bioceramic compositions|
|US20080089930 *||Nov 27, 2007||Apr 17, 2008||Keraplast Technologies, Ltd.||Keratin-Based Powders and Hydrogel for Pharmaceutical Applications|
|US20090004242 *||Feb 15, 2007||Jan 1, 2009||Van Dyke Mark E||Coatings and Biomedical Implants Formed From Keratin Biomaterials|
|US20090148488 *||Feb 20, 2009||Jun 11, 2009||Keraplast Technologies, Ltd.||Bioactive coating for medical devices|
|US20110070276 *||Feb 26, 2009||Mar 24, 2011||Keraplast Technologies, Ltd.||Bioactive keratin peptides|
|US20110137329 *||Jan 18, 2011||Jun 9, 2011||Dyke Mark E Van||Nerve regeneration employing keratin biomaterials|
|US20110142910 *||Feb 16, 2007||Jun 16, 2011||Van Dyke Mark E||Clotting and Healing Compositions Containing Keratin Biomaterials|
|US20110217285 *||Mar 8, 2011||Sep 8, 2011||Van Dyke Mark E||Keratin biomaterials for treatment of ischemia|
|US20110217356 *||Mar 7, 2011||Sep 8, 2011||Van Dyke Mark E||Controlled delivery system|